Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy

Background: Lenvatinib is recommended as a first-line tyrosine kinase inhibitor for advanced hepatocellular carcinoma (HCC) since 2017. The aim of this study was to compare the clinical action of lenvatinib in hepatitis B virus (HBV)-related HCC and hepatitis C virus (HCV)-related HCC. Methods: A co...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaomi, Wang, Jingyan, Ding, Xiaoyan, Xu, Yawen, Yu, Minghua, Wu, Hongxiao, Deng, Na, Li, Wei, Chen, Jinglong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871375/
https://www.ncbi.nlm.nih.gov/pubmed/36703739
http://dx.doi.org/10.3389/fphar.2022.1032881

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871375/
https://www.ncbi.nlm.nih.gov/pubmed/36703739
http://dx.doi.org/10.3389/fphar.2022.1032881

Ejemplares similares